Humana Inc. $HUM Shares Sold by Tobam

Tobam reduced its position in shares of Humana Inc. (NYSE:HUM) by 36.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 11,910 shares of the insurance provider’s stock after selling 6,754 shares during the period. Tobam’s holdings in Humana were worth $3,099,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. Revolve Wealth Partners LLC acquired a new stake in shares of Humana during the 4th quarter worth approximately $202,000. Woodline Partners LP grew its position in Humana by 460.0% in the first quarter. Woodline Partners LP now owns 10,192 shares of the insurance provider’s stock worth $2,697,000 after acquiring an additional 8,372 shares during the period. Sivia Capital Partners LLC increased its stake in Humana by 53.7% during the second quarter. Sivia Capital Partners LLC now owns 1,293 shares of the insurance provider’s stock worth $316,000 after acquiring an additional 452 shares during the last quarter. Atria Wealth Solutions Inc. increased its stake in Humana by 10.3% during the second quarter. Atria Wealth Solutions Inc. now owns 955 shares of the insurance provider’s stock worth $234,000 after acquiring an additional 89 shares during the last quarter. Finally, Ritholtz Wealth Management purchased a new stake in Humana in the second quarter valued at $538,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

HUM has been the subject of a number of research analyst reports. Raymond James Financial lowered their price target on Humana from $340.00 to $230.00 and set an “outperform” rating for the company in a report on Friday. Jefferies Financial Group decreased their target price on shares of Humana from $310.00 to $235.00 and set a “buy” rating on the stock in a research report on Thursday. TD Cowen dropped their price target on shares of Humana from $260.00 to $173.00 and set a “hold” rating for the company in a research report on Friday. The Goldman Sachs Group decreased their price objective on shares of Humana from $215.00 to $158.00 and set a “sell” rating on the stock in a report on Friday. Finally, Guggenheim lowered their price objective on shares of Humana from $312.00 to $252.00 and set a “buy” rating for the company in a research report on Thursday. Seven analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and five have issued a Sell rating to the company’s stock. According to data from MarketBeat, Humana presently has an average rating of “Hold” and an average price target of $238.29.

Humana News Roundup

Here are the key news stories impacting Humana this week:

• Positive Sentiment: CenterWell (Humana’s healthcare services unit) closed the acquisition of MaxHealth, adding a sizable Florida primary‑care network (~82 owned/affiliated clinics and >80,000 patients in value‑based programs) which expands Humana’s senior-focused, value‑based primary care footprint and accelerates revenue and membership growth in higher-value care. CenterWell Completes Acquisition of MaxHealth
• Positive Sentiment: Management signals more primary‑care deals may be coming (CEO remarks and media reports about a potential ~$1B strategic push), reinforcing the company’s strategy to grow value‑based care capacity — a long‑term growth catalyst if Humana can scale clinics and convert MA members to higher‑margin care. Humana CEO hints at upcoming primary care deal
• Neutral Sentiment: Jefferies cut its price target (from $310 to $235) but kept a Buy rating, reflecting disagreement among analysts on Humana’s growth vs. margin tradeoff — some firms still see upside despite lower near‑term earnings visibility. Jefferies price target change
• Negative Sentiment: Several major analysts materially lowered price targets and trimmed estimates (TD Cowen to $173 Hold; JPMorgan to $180 Neutral; Evercore, Cantor, Leerink also cut targets), reflecting concern that Medicare Advantage cost pressures, lower quality (STAR) ratings, and a cautious 2026 earnings guide will weigh on near‑term profitability. TD Cowen PT cut
• Negative Sentiment: Humana reported a fourth‑quarter loss and issued a cautious 2026 outlook (management flagged sharply lower near‑term earnings as Medicare Advantage membership surges but margins remain under pressure), which prompted analysts to slash forecasts and is the primary fundamental reason for downward pressure on the stock. Humana stock falls on disappointing earnings forecast

Humana Trading Up 2.8%

Shares of HUM stock opened at $183.92 on Monday. Humana Inc. has a fifty-two week low of $169.61 and a fifty-two week high of $315.35. The company has a 50 day moving average price of $244.65 and a 200 day moving average price of $261.02. The stock has a market capitalization of $22.12 billion, a P/E ratio of 18.73, a price-to-earnings-growth ratio of 1.96 and a beta of 0.44. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.02 and a current ratio of 2.00.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) EPS for the quarter, beating the consensus estimate of ($4.01) by $0.05. The company had revenue of $32.64 billion during the quarter, compared to analysts’ expectations of $32.08 billion. Humana had a net margin of 0.92% and a return on equity of 11.43%. The firm’s revenue was up 11.3% compared to the same quarter last year. During the same quarter last year, the company posted ($2.16) EPS. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. Equities research analysts predict that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.